PMID- 29130133
OWN - NLM
STAT- MEDLINE
DCOM- 20180111
LR  - 20180710
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 97
IP  - 2
DP  - 2018 Feb
TI  - Infusion of leukocytes from HLA haplo-identical familial donors as an adjuvant in 
      the HLH-2004 protocol to treat the virus-associated adult hemophagocytic 
      lymphohistiocytosis: a retrospective study of 26 patients.
PG  - 319-326
LID - 10.1007/s00277-017-3174-8 [doi]
AB  - Adult hemophagocytic lymphohistiocytosis (HLH) is a fatal disease with poor 
      survival and a limited role of drug therapies. To help to recognize virus and 
      enhance survival, we infused leukocytes derived from human leukocyte antigen 
      (HLA) haplo-identical familial donors to patients. We retrospectively 
      investigated 26 adult virus-associated hemophagocytic syndrome (VAHS) patients' 
      medical records from 2006-2017. Eleven of the 26 patients accepted relatives' 
      derived leukocytes infusions in addition to drug therapies recommended in the 
      HLH-2004 protocol. The leukocyte doses ranged from 0.75 to 3.30x10(8) per 
      kilogram of body weight. The other 15 patients accepted immunosuppressive and 
      supportive therapies referred to in the HLH-2004 protocol. We compared the 
      treatment outcomes of the two groups of patients. Patients in the cell infusion 
      group had a lower viral load (P = 0.023) and better laboratory results and 
      prolonged overall survival (60.44 vs. 20.18 weeks, P = 0.047). A factor that 
      might relate to overall survival is platelet count (P = 0.032), except for the 
      leukocyte infusions (P = 0.012). For patients without acceptable donors, 
      infusions of leukocytes from HLA haplo-identical familial donors could be a 
      feasible treatment to prolong overall survival as an adjuvant to drug therapies.
FAU - Zhang, Hui
AU  - Zhang H
AD  - Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, Shaanxi, P.R. China.
FAU - Dai, Zhiming
AU  - Dai Z
AD  - Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, Shaanxi, P.R. China.
FAU - Yang, Nan
AU  - Yang N
AD  - Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, Shaanxi, P.R. China.
FAU - Wang, Jin
AU  - Wang J
AD  - Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, Shaanxi, P.R. China.
FAU - He, Aili
AU  - He A
AD  - Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, Shaanxi, P.R. China.
FAU - Wang, Jianli
AU  - Wang J
AD  - Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, Shaanxi, P.R. China.
FAU - Zhang, Yang
AU  - Zhang Y
AD  - Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, Shaanxi, P.R. China.
FAU - Meng, Shan
AU  - Meng S
AD  - Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, Shaanxi, P.R. China.
FAU - Wang, Baiyan
AU  - Wang B
AD  - Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, Shaanxi, P.R. China.
FAU - Sun, Rong
AU  - Sun R
AD  - Department of Gynecology & Obstetrics, Obstetrics and Gynecology Hospital of 
      Fudan University, Shanghai, 200011, P.R. China.
FAU - Zhang, Wanggang
AU  - Zhang W
AD  - Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, Shaanxi, P.R. China. zhangwanggang2003@yahoo.com.
LA  - eng
GR  - No.2014KTCL03-01/science and technology coordinating innovative engineering 
      project of Shaanxi Province/
PT  - Journal Article
DEP - 20171112
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antiviral Agents)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 5968Y6H45M (entecavir)
RN  - 5Z93L87A1R (Guanine)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - P9G3CKZ4P5 (Ganciclovir)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage
MH  - Adolescent
MH  - Adult
MH  - Antiviral Agents/*therapeutic use
MH  - Cyclosporine/therapeutic use
MH  - Dexamethasone/therapeutic use
MH  - Epstein-Barr Virus Infections/immunology/mortality/*therapy/virology
MH  - Family
MH  - Female
MH  - Ganciclovir/therapeutic use
MH  - Guanine/analogs & derivatives/therapeutic use
MH  - Haplotypes
MH  - Herpesvirus 4, Human/drug effects/immunology/pathogenicity
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - *Leukocyte Transfusion
MH  - Leukocytes/cytology/immunology
MH  - Lymphohistiocytosis, Hemophagocytic/immunology/mortality/*therapy/virology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Tissue Donors
MH  - Treatment Outcome
MH  - Viral Load/drug effects
OTO - NOTNLM
OT  - Conventional therapy
OT  - Hemophagocytic lymphohistiocytosis
OT  - Leukocytes infusion
OT  - Overall survival
EDAT- 2017/11/14 06:00
MHDA- 2018/01/13 06:00
CRDT- 2017/11/14 06:00
PHST- 2017/04/23 00:00 [received]
PHST- 2017/11/05 00:00 [accepted]
PHST- 2017/11/14 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
PHST- 2017/11/14 06:00 [entrez]
AID - 10.1007/s00277-017-3174-8 [pii]
AID - 10.1007/s00277-017-3174-8 [doi]
PST - ppublish
SO  - Ann Hematol. 2018 Feb;97(2):319-326. doi: 10.1007/s00277-017-3174-8. Epub 2017 
      Nov 12.